NCT04828603 Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
| NCT ID | NCT04828603 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Allergy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2007-10 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2007-10 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to strengthen our ability to accurately diagnose allergies and understand cellular, humoral, genetic components and physiological changes in allergic disease
Eligibility Criteria
Inclusion Criteria: * Any individual with possible allergy Exclusion Criteria: * Patients with special risks attendant to venipuncture will be excluded
Contact & Investigator
R. Sharon Chinthrajah, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT04828603 clinical trial?
This trial is open to participants of all sexes, aged 1 Week or older, up to 90 Years, studying Allergy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04828603 currently recruiting?
Yes, NCT04828603 is actively recruiting participants. Contact the research team at snpcenterallergy_inquiry@stanford.edu for enrollment information.
Where is the NCT04828603 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT04828603 clinical trial?
NCT04828603 is sponsored by Stanford University. The principal investigator is R. Sharon Chinthrajah, MD at Stanford University. The trial plans to enroll 2,500 participants.